BioSpace News Archive

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that its management will present at the Jefferies Global Healthcare Conference at 4:00pm EDT on Wednesday, June 5, 2024.

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2024 Jefferies Global Healthcare Conference in New York City.

Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced the election of the 10 directors nominated at its 2024 annual meeting of shareholders held on May 29, 2024.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences.

NovaBay® Pharmaceuticals, Inc. announces that a quorum was reached and that all proposals in the Company’s Definitive Proxy Statement filed on April 18, 2024 with the Securities and Exchange Commission were approved by stockholders at its 2024 Annual Meeting of Stockholders held on May 28, 2024.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has approved AUSTEDO XR as a one pill, once-daily treatment option, now with four new tablet strengths indicated in adults for TD and HD chorea.

Bruker Corporation announced the pricing of its previously announced underwritten registered public offering of 6,000,000 shares of its common stock.

Novotech, the global full-service clinical Contract Research Organization that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, announced it has signed a Memorandum of Understanding with Hong Kong-Shenzhen Innovation and Technology Park Limited.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced preclinical data supporting the potential of ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy candidate for the treatment of B-cell driven autoimmune diseases.

Certara, Inc., a global leader in biosimulation, announced that Company management will participate in the Jefferies Global Healthcare Conference.